Sort
130,381 grants matching “hiv”
LENTIVIRUS-BASED IMMUNOTHERAPY FOR AIDS
$1,781,843John A Zaia · Beckman Research Institute/City Of Hope · P01 · FY2007 · AI
PS10-10138, EXPANDED HIV TESTING FOR DISPROPORTIONATELY AFFECTED POPULATIONS
$1,781,457Greduvel Duran-Guzman · Puerto Rico Department Of Health · U62 · FY2010 · PS
Reducing HIV vulnerability through a multilevel life skills intervention for adolescent men
$1,781,404Jose Arturo Bauermeister · University Of Pennsylvania · U01 · FY2019 · MD
Kidney Transplantation from Donors with HIV: Impact on Rejection and Long-term Outcomes
$1,781,226Christine Marie Durand · Johns Hopkins University · U01 · FY2023 · AI
Adjuvant Comparison and Characterization (HIV)
$1,780,989Bali Pulendran · Stanford University · N01 · FY2023 · AI
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Laboratory Center
$1,780,794Grace M. Aldrovandi · University Of California Los Angeles · UM1 · FY2016 · AI
Vaccine and Treatment Evaluation Unit at Saint Louis University
$1,780,596Daniel F. Hoft · Saint Louis University · UM1 · FY2022 · AI
Immunization and Immune Monitoring
$1,780,229David C Montefiori · Duke University · U19 · FY2008 · AI
Manufacturing and Regulatory Support of Ad/MVA and Ad/Protein HIV-1 Vaccines
$1,779,755Jaap Goudsmit · Beth Israel Deaconess Medical Center · U19 · FY2014 · AI
Adeno-associated Virus Biology And Utilization For Gene Transfer
$1,779,582John A Chiorini · Dental & Craniofacial Research · Z01 · FY2007 · DE
Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet)
$1,779,363Catherine C McGowan · Vanderbilt University Medical Center · U01 · FY2017 · AI
RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN
$1,779,078Barbara Driver · Westat, Inc. · N01 · FY2018 · HD
HIV Reservoir Dynamics Associated with Metabolic Complications of HIV Infection
$1,778,953Timothy W Schacker · University Of Minnesota · R01 · FY2025 · DK
Tfh and B cells in HIV/SIV pathogenesis and vaccination
$1,778,916Richard A Koup · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
ESSENTIAL CORE ACTIVITIES, NIAID PRECLINICAL DEVELOPMENT SUPPORT
$1,778,848Thomas Vancott · Advanced Bioscience Laboratories, Inc. · N01 · FY2018 · AI
HOPE in Action: A Clinical Trial of HIV-to-HIV Liver Transplantation
$1,778,541Christine Marie Durand · Johns Hopkins University · U01 · FY2018 · AI
University of Miami Pediatric Perinatal HIV/AIDS Clinical Trails Unit
$1,778,367Gwendolyn B. Scott · University Of Miami School Of Medicine · U01 · FY2011 · AI
RT Inhibitor CSIC and Entry Inhibitor Retrocyclin RC101 as Microbicides
$1,778,287Phalguni Gupta · University Of Pittsburgh At Pittsburgh · U19 · FY2011 · AI
The Multi-omics Vaccine Evaluation (MOVE) Consortium
$1,778,269Bryan Briney · Scripps Research Institute, The · P01 · FY2024 · AI
UCSF Prevention Research Center
$1,778,203Marguerita A Lightfoot · University Of California, San Francisco · U48 · FY2017 · DP
Studies of Host Cellular Proteins Required for viral Budding and release
$1,777,897Fadila Bouamr · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Novel approaches for vaccine design
$1,777,832Michel C Nussenzweig · Rockefeller University · P01 · FY2009 · AI
HIV Neurobehavioral Research Center
$1,777,614Robert Kernachan Heaton · University Of California, San Diego · P30 · FY2015 · MH
HIV Neurobehavioral Research Center
$1,777,614Robert Kernachan Heaton · University Of California, San Diego · P30 · FY2014 · MH
Adjuvant Development within the context of a vaccine to protect against B. pertussis for use in newborns.
$1,777,596Ofer Levy · Boston Children'S Hospital · N01 · FY2019 · AI